{
  "id": 1494,
  "text": "CCRT by tegafur-uracil and carboplatin did not show any significant advantage in tumour response rate, PFS, OS or treatment toxicity over CCRT with carboplatin alone.The RCT1467 comparing, showed that treatment with interferon alpha-2b plus 13-cis-retinoic acid with radiation did not demonstrate survival or response rate advantage over cisplatin plus radiation despite being less toxic.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: CCRT by tegafur-uracil and carboplatin did not show any significant advantage in tumour response rate, PFS, OS or treatment toxicity over CCRT with carboplatin alone.The RCT1467 comparing, showed that treatment with interferon alpha-2b plus 13-cis-retinoic acid with radiation did not demonstrate survival or response rate advantage over cisplatin plus radiation despite being less toxic.\n\n<question>: ",
  "ChatGPT_response_0": "根据临床试验的比较，对于治疗肿瘤时的药物组合或方案，目前尚未发现明显优势的选择。例如，通过研究发现，使用替加呋酮与卡铂的同步放疗与单独使用卡铂进行同步放疗相比，并未表现出肿瘤反应率、PFS、OS或治疗毒性方面的显著优势。另外，进行的RCT1467比较研究显示，与顺铂联合放疗相比，使用干扰素α-2b加13-顺式维甲酸联合放疗并未表现出更好的生存率或反应率，尽管毒性更小。因此，在目前的研究中，尚未发现一种药物组合或方案在肿瘤反应率、PFS、OS和治疗毒性方面表现最佳的选择。",
  "query": "在治疗肿瘤时，有多种药物组合和方案可供选择。通过临床试验的比较，您认为哪种药物组合或方案在肿瘤反应率、PFS、OS和治疗毒性方面表现最佳？给您的选择理由是什么？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗肿瘤时，有多种药物组合和方案可供选择。通过临床试验的比较，您认为哪种药物组合或方案在肿瘤反应率、PFS、OS和治疗毒性方面表现最佳？给您的选择理由是什么？\n\n<reference text>: CCRT by tegafur-uracil and carboplatin did not show any significant advantage in tumour response rate, PFS, OS or treatment toxicity over CCRT with carboplatin alone.The RCT1467 comparing, showed that treatment with interferon alpha-2b plus 13-cis-retinoic acid with radiation did not demonstrate survival or response rate advantage over cisplatin plus radiation despite being less toxic.\n\n<reply>: ",
  "response": "根据临床试验的比较，对于治疗肿瘤时的药物组合或方案，目前尚未发现明显优势的选择。例如，通过研究发现，使用替加呋酮与卡铂的同步放疗与单独使用卡铂进行同步放疗相比，并未表现出肿瘤反应率、PFS、OS或治疗毒性方面的显著优势。另外，进行的RCT1467比较研究显示，与顺铂联合放疗相比，使用干扰素α-2b加13-顺式维甲酸联合放疗并未表现出更好的生存率或反应率，尽管毒性更小。因此，在目前的研究中，尚未发现一种药物组合或方案在肿瘤反应率、PFS、OS和治疗毒性方面表现最佳的选择。"
}